Introduction
============

Malignant tumor represents an enormous economic burden on society in both developing and developed countries. According to 32 GLOBOCAN estimates, approximately 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide, especially in the developing countries.[@b1-ott-11-1801] Cancer is a complex multifaceted disease that results from gene--environment interactions. Apart from the common factors such as smoking, obesity, and less physical activity, the genetic variations, including single nucleotide polymorphisms (SNPs), have been reported to be associated with malignant tumor susceptibility. The WWOX gene, located on chromosome 16q23.3-24.1, has been reported to play an anticancer role by regulating signaling pathways and cellular functions.[@b2-ott-11-1801]--[@b4-ott-11-1801] In addition, both in vivo and in vitro studies have indicated that WWOX can induce apoptosis by interacting with p53 and p73.[@b5-ott-11-1801]--[@b7-ott-11-1801] Low expression and abnormal transcription of WWOX has been found in several types of cancer, including lung cancer, prostate cancer, breast cancer, and oral cancer.[@b8-ott-11-1801]--[@b13-ott-11-1801] Moreover, the low expression of this gene is correlated with higher tumor stages and worse prognosis in patients.[@b14-ott-11-1801] In several studies, SNPs of WWOX gene have been identified as a potentially genetic risk factor in malignant tumors including lung cancer, gastric cancer, thyroid cancer, esophageal cancer, and osteosarcoma.[@b15-ott-11-1801]--[@b20-ott-11-1801] However, other studies indicated that there were no significant associations.[@b21-ott-11-1801],[@b22-ott-11-1801] Because of relatively small sample sizes, these studies provided limited evidence and might have been underpowered to detect the overall effects. Therefore, we conducted this study to obtain a more precise estimation from all eligible case--control studies.

Methods
=======

Primary search strategy
-----------------------

We systematically searched PubMed, Google Scholar, and Chinese National Knowledge Infrastructure comprehensively for all publications regarding the association between the WWOX polymorphisms and the malignant tumor risk (up to August 30, 2017), by using the combinations of the following keywords: WWOX, variants/polymorphism/SNP, and malignant tumor. Additional usable data were hand-searched from reference lists of original studies or review articles. Nevertheless, if several studies were performed on the same subjects, only the one with latest and/or largest sample size would be involved. Ethical approval was not necessary because this was a meta-analysis, including no direct handing of personal data or recruitment of subjects.

Inclusion and exclusion criteria
--------------------------------

Studies involved had to satisfy the following inclusion criteria: case--control design was utilized; the diagnosis of the patients with cancer should be pathologically confirmed and the controls were verified as free from any cancer; and sufficient data for estimating an odds ratio (OR) with 95% CI was available. The major exclusion criteria were as follows: no obtainable genotype frequency data; duplicates of previous publication; and studies designed as a case--case or case-only study.

Data extraction
---------------

The identified studies were reviewed separately by two investigators (HY, YW) independently and carefully to determine whether an individual study was eligible for the analysis. These data were extracted from studies involved independently, and the disagreement was resolved by a discussion involving a senior investigator (KJ). All the following data were sought from each study and recorded in a standardized form: first author's name; year of publication; ethnicity of each study population; source of controls; sample size; genotyping method; number of cases and controls; and frequencies of rs3764340, rs12918952, and rs383362 in cases and controls, respectively; and results of the Hardy-- Weinberg equilibrium (HWE) test.

Statistical analysis
--------------------

The pooled ORs with 95% CIs were applied to evaluate the strength of association between WWOX rs3764340 C\>G, rs12918952 G\>A, and rs383362 G\>T polymorphisms and malignant tumor susceptibility. The fixed-effects model (the Mantel--Haenszel method) and the random-effects model (the DerSimonian--Laird method) were separately employed to pool the data.[@b23-ott-11-1801] If existence of heterogeneity was detected, the random-effects model would be more appropriate. Sensitivity analysis was performed to assess the influence of individual studies on the pooled ORs, with the method of calculating the outcomes again by omitting one single study each time. After that, subgroup analyses based on the source of controls was further carried out to identify the potential association for each subgroup. Begg's funnel plots and Egger's linear regression method were taken to estimate the publication bias, and a *P*\<0.05 was set as the significance threshold.[@b24-ott-11-1801] HWE was checked by the goodness-of-fit chi-square test, and a *P*\<0.05 was considered as a significantly selective bias.[@b25-ott-11-1801]

Stata software (version 12.0; StataCorp LP, College Station, TX, USA) was employed in the whole statistical analyses. *P*-values were all two-sided and regarded as statistically significant if less than 0.05.

Results
=======

Studies characteristics
-----------------------

The flowchart of study exclusion and inclusion criteria with specific reasons is indicated in [Figure 1](#f1-ott-11-1801){ref-type="fig"}. We identified 30 records, among which 14 articles appeared to be potentially eligible for inclusion and were retrieved in full texts. After full-text review, six articles were excluded due to no detailed data. Therefore, a total of eight case--control studies were ultimately included in the meta-analysis,[@b15-ott-11-1801]--[@b22-ott-11-1801] and the details of each study were recorded in [Table 1](#t1-ott-11-1801){ref-type="table"}. Among them, eight articles containing 6,177 cases and 6,606 controls surveyed the association between rs3764340 C\>G and malignant tumor risk.[@b15-ott-11-1801]--[@b22-ott-11-1801] Four studies on the relation between rs12918952 G\>A and malignant tumor risk included 2,447 cases and 3,249 controls,[@b18-ott-11-1801],[@b20-ott-11-1801]--[@b22-ott-11-1801] and four publications containing 2,950 cases and 3,872 controls explored the correlation of rs383362 G\>T with malignant tumor risk.[@b18-ott-11-1801],[@b20-ott-11-1801]--[@b22-ott-11-1801] The genotyping methods used to detect the WWOX polymorphisms included sequencing, MassARRAY^®^ System (Agena Bioscience, Inc., San Diego, CA, USA), polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP), and TaqMan^®^ (Thermo Fisher Scientific, Waltham, MA, USA). Furthermore, we divided them into population-based group or hospital-based group in all studies to distinguish between different sources of control group. For the WWOX rs3764340 polymorphism, the studies consisted of three population-based controls[@b16-ott-11-1801],[@b17-ott-11-1801],[@b21-ott-11-1801] and five hospital-based controls.[@b15-ott-11-1801],[@b18-ott-11-1801]--[@b20-ott-11-1801],[@b22-ott-11-1801] For rs12918952 G\>A and rs383362 G\>T, one population-based control[@b21-ott-11-1801] and three hospital-based controls[@b18-ott-11-1801],[@b20-ott-11-1801],[@b22-ott-11-1801] were included in these studies, respectively. We used subgroup analyses to explore the effects of different sources of control and genotyping methods on the associations of increased risk of tumor with the WWOX rs3764340 C\>G, rs12918952 G\>A, and rs383362 G\>T polymorphisms. In addition, the studied tumor type included gastric cancer, lung cancer, oral cancer, osteosarcoma, thyroid carcinoma, hepatocellular carcinoma, and esophageal cancer.

Quantitative synthesis results
------------------------------

The results for the association of WWOX rs3764340 C\>G with malignant tumor risk are summarized in [Table 2](#t2-ott-11-1801){ref-type="table"}. Overall, neither the homozygous nor recessive genetic models found significant associations between rs3764340 C\>G and malignant tumor risk (GG vs CC: OR=1.36, 95% CI: 0.90--2.04, *P*=0.392; GG vs CC/GC: OR=1.30, 95% CI: 0.88--1.93, *P*=0.451). The heterozygote and dominant genetic models witness obvious association between the SNPs and cancer risk ([Figure 2](#f2-ott-11-1801){ref-type="fig"}) (CG vs CC: OR=1.31, 95% CI: 1.12--1.53, *P*=0.031; GG/CG vs CC: OR=1.31, 95% CI: 1.11--1.54, *P*=0.014). The allele analysis also found significant association (G vs C: OR=1.28, 95% CI: 1.09--1.50, *P*=0.009). For the different genotyping methods, rs3764340 C\>G demonstrated increased risk of cancer both in the PCR-RFLP subgroup (CG vs CC: OR=1.46, 95% CI: 1.24--1.72, *P*=0.691; GG vs CC: OR=1.14, 95% CI: 0.53--2.45, *P*=0.239; GG/CG vs CC: OR=1.44, 95% CI: 1.23--1.68, *P*=0.532; GG vs CC/GC: OR=1.09, 95% CI: 0.51--2.32, *P*=0.248; G vs C: OR=1.38, 95% CI: 1.09--1.50, *P*=0.349) and in the TaqMan subgroup (CG vs CC: OR=1.32, 95% CI: 1.10--1.59, *P*=0.236; GG vs CC: OR=1.58, 95% CI: 0.94--2.66, *P*=0.566; GG/CG vs CC: OR=1.35, 95% CI: 1.10--1.66, *P*=0.158; GG vs CC/GC: OR=1.50, 95% CI: 0.90--2.52, *P*=0.651; G vs C: OR=1.34, 95% CI: 1.09--1.63, *P*=0.133). For the subgroup analysis according to the source of control, significant association between rs3764340 C\>G and malignant tumor risk was found only in population-based group (CG vs CC: OR=1.33, 95% CI: 1.09--1.61, *P*=0.312; GG/CG vs CC: OR=1.35, 95% CI: 1.11--1.65, *P*=0.263; G vs C: OR=1.34, 95% CI: 1.11--1.63, *P*=0.236).

The results for the association of WWOX rs383362 with malignant tumor risk are summarized in [Table 3](#t3-ott-11-1801){ref-type="table"}. Overall, all genotypes were not significantly associated with the risk of malignant tumor (TG vs GG: OR=1.14, 95% CI: 0.89--1.45, *P*=0.008; TT vs GG: OR=1.04, 95% CI: 0.55--1.97, *P*=0.130; TT+GT vs GG: OR=1.13, 95% CI: 0.87--1.47, *P*=0.002; TT vs GT+GG: OR=1.02, 95% CI: 0.57--1.81, *P*=0.186). Similarly, no significant association was observed in the allele analysis (T allele vs G allele: OR=1.10, 95% CI: 0.86--1.41, *P*=0.002). In the subgroup analysis according to genotyping methods ([Figure 3](#f3-ott-11-1801){ref-type="fig"}), the rs383362 G\>T was associated with higher risk of malignant tumor in the TaqMan subgroup (TG vs GG: OR=1.35, 95% CI: 1.16--1.56, *P*=0.379; TT vs GG: OR=1.51, 95% CI: 1.03--2.22, *P*=0.758; TT+GT vs GG: OR=1.36, 95% CI: 1.18--1.57, *P*=0.364; TT vs GT+GG: OR=1.40, 95% CI: 0.95--2.05, *P*=0.811). The same result was found in the allele analysis (T allele vs G allele: OR=1.31, 95% CI: 1.16--1.49, *P*=0.370).

[Table 4](#t4-ott-11-1801){ref-type="table"} shows the results for the association between rs12918952 G\>A and cancer risk. Over all, no significant association was observed in any of the compared genetic models (AG vs GG: OR=1.06, 95% CI: 0.90--1.26, *P*=0.523; AA vs GG: OR=2.18, 95% CI: 0.62--0.768, *P*=0.216; AA+AG vs GG: OR=1.09, 95% CI: 0.92--1.29, *P*=0.38; AA vs AG+GG: OR=2.15, 95% CI: 0.62--7.49, *P*=0.223). Also, no significant association was revealed in the allele analysis (A allele vs G allele: OR=1.12, 95% CI: 0.92--1.35, *P*=0.254). However, a different result was found in the PCR-RFLP subgroup ([Figure 4](#f4-ott-11-1801){ref-type="fig"}) (AA vs GG: OR=7.46, 95% CI: 1.17-- 47.48, *P*=0.446; AA vs AG+GG: OR=7.31, 95% CI: 1.15--46.49, *P*=0.445) in the analysis according to different genotyping methods.

Heterogeneity test and sensitivity analysis
-------------------------------------------

In most comparisons of WWOX rs3764340, rs383362, and rs12918952 polymorphisms, obvious heterogeneity was observed (figure not shown). We next performed a leave-one-out sensitivity analysis. The results of associations for WWOX rs3764340, rs383362, and rs12918952 polymorphisms in three important types of models are listed in [Figure S1](#SD1-ott-11-1801){ref-type="supplementary-material"}, which demonstrated stability and reliability of results for such associations.

Publication bias
----------------

We assessed the potential publication bias for three types of models (dominant model, heterozygous model, and allele model) by the Begg's test and Egger's test, and the results are shown in [Table 5](#t5-ott-11-1801){ref-type="table"}. No obvious symmetric distribution was found, indicating no evidence of significant publication bias. The overall results revealed that our results were statistically reliable.

Discussion
==========

WWOX, a protein with the WW domain, is conserved in all eukaryotes and has a significant role in cell signaling or regulation, such as regulating the protein degradation, mitosis, apoptosis, transcription, and RNA splicing process.[@b26-ott-11-1801] Low or reduced expression of the WWOX protein was found in a variety of human malignancies, which may lead to the deregulation of these pathways. The silencing of the WWOX protein expression was observed very early in tumor development, which may result in the transformation of normal cells to malignant cells. The same result was found in the knock-out mice experiments.[@b3-ott-11-1801] Based on the research of Maeda et al, low or reduced expression of WWOX was observed in gastric carcinoma cell lines (HSC-45, HSC-57, HSC-59, MKN-7, and MKN-74). Moreover, the gastric tumor tissue analyses showed that the loss of WWOX expression in 33% of cases was associated with poorer clinical findings.[@b27-ott-11-1801] In addition, according to the studies of Dias et al, 91% of subjects with papillary thyroid carcinomas had a decreased expression of WWOX in the tumor tissue. Thus, it might indicate that the reduced expression of WWOX is the reason for cell proliferation, leading to further genomic instability.[@b28-ott-11-1801]

Polymorphisms have been identified as a powerful tool for predicting hereditary susceptibility of some complex diseases including malignant tumor.[@b29-ott-11-1801] However, previous individual studies about the association between WWOX polymorphisms and malignant tumor risk were not only limited but also inconclusive. To our knowledge, this is the first comprehensive analysis researching the possible relationship of WWOX SNPs (rs3764340, rs383362, and rs12918952) with cancer susceptibility, which will be of benefit to provide new biomarkers for screening high-risk populations for malignant tumor and promoting the process of molecular-targeted therapy.

Rs3764340 C\>G, which is located in exon 8, was associated with increased risk of multiple cancers.[@b15-ott-11-1801]--[@b18-ott-11-1801],[@b20-ott-11-1801] Based on the bioinformatics analysis, rs3764340 C\>G is an exonic splicing enhancer which can promote the process of pre-mRNA splicing. Therefore, it is possible that this SNP may enhance the selective splicing in exon 8, leading to a high incidence of deletion of the exon.[@b30-ott-11-1801] Another study also reported that the SNP may change the conformation of the WWOX protein.[@b15-ott-11-1801] In this study, we found that WWOX 3764340 C\>G was associated with risk of overall malignant tumor in the dominant model, heterozygous model, and allele model. In addition, in the subgroup analysis of different sources of controls, evidence of an association between the rs3764340 polymorphism and an increased cancer risk was only found in the population-based studies, but not in the hospital-based studies, which was probably caused by the fact that the controls recruited from hospital could not represent the general population well.

We did not find obvious association between SNP rs383362, rs12918952, and malignant tumor risk in any genetic comparison. In addition, only in the subgroup of TaqMan, WWOX rs38336 was constantly associated with increased tumor risk in all the compared genetic models. However, when it came to WWOX rs12918952, the association was only found in the subgroup of PCR-RFLP, which indicated that different genotyping methods might influence the results. It is worth noting that only four case-- control studies were available for rs383362 and rs12918952 polymorphism analysis, and the sample size was not large enough. Therefore, the results should be interpreted with caution.

Some limitations of our meta-analysis should be noted. First, the number of studies was not sufficiently large, especially for subgroup analysis of WWOX rs383362 and rs12918952. Second, the languages of the publications were limited to English and Chinese. Finally, the lack of original data in some valuable research articles limited us to continue researching some potential interactions, such as age, sex, family history, environmental factors, and lifestyle. Consequently, it is required that a more precise analysis be performed if individual data were available.

Conclusion
==========

The WWOX rs3764340 GG+CG and CG genotypes may increase cancer risk. However, rs383362 and rs12918952 polymorphisms may have no significant association with malignant tumor risk. Further large-scale and well-designed investigations including different cancers are required to verify the findings of this study.

Supplementary materials
=======================

###### 

The influence of individual studies on the overall odds ratio under (**A**) allele model (G vs C) for WWOX rs3764340 C\>G, (**B**) allele model (T vs G) for WWOX rs383362 G\>T, and (**C**) allele model (A vs G) for WWOX rs12918952 G\>A.
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###### 

Forest plots for the association between WWOX rs3764340 C\>G polymorphism and malignant tumors risk: (**A**) CG vs CC, (**B**) GG/CG vs CC, and (**C**) G vs C.

**Note:** Weights are from random effects analysis.
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###### 

Forest plots for the association between WWOX rs383362 G\>T polymorphism and risk of malignant tumor in the subgroup of genotyping methods: (**A**) TG vs GG and (**B**) T allele vs G allele.

**Note:** Weights are from random effects analysis.
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![Forest plots for the association between WWOX rs12918952 G\>A polymorphism and malignant tumor risk in the subgroup of genotyping methods: (**A**) AA vs GG and (**B**) AA vs AG+GG.\
**Note:** Weights are from random effects analysis.](ott-11-1801Fig4){#f4-ott-11-1801}

###### 

Characteristics of the included studies in this meta-analysis

  Study                                           Year   Ethnicity   SOC   Cancer type                Genotyping method   Case    Control   *P*-value (HWE test)                                   
  ----------------------------------------------- ------ ----------- ----- -------------------------- ------------------- ------- --------- ---------------------- ---- ------- ------- ----- ---- --------
  **For WWOX rs3764340 C**\>**G polymorphism**                                                                                                                                                     
                                                                                                                                                                                                   
  Wang et al[@b19-ott-11-1801]                    2016   Asian       HB    Lung tumor                 Mass Array          500     425       74                     1    500     406     91    3    0.38
  Cheng et al[@b21-ott-11-1801]                   2016   Asian       PB    Oral tumor                 TaqMan              761     630       123                    8    1,199   1,016   173   10   0.3834
  Huang et al[@b18-ott-11-1801]                   2011   Asian       HB    Lung tumor                 TaqMan              1,559   1,304     240                    15   1,679   1,465   202   12   0.1038
  Cancemi et al[@b15-ott-11-1801]                 2011   Caucasian   HB    Thyroid tumor              PCR-RFLP            1,741   1,528     209                    4    1,042   955     83    4    0.73
  Guo et al[@b17-ott-11-1801]                     2013   Asian       PB    Gastric tumors             PCR-RFLP            504     415       81                     8    596     523     67    6    0.025
  Guo et al[@b16-ott-11-1801]                     2013   Asian       PB    Esophageal tumor           PCR-RFLP            482     397       76                     9    596     523     67    6    0.025
  Zhang et al[@b20-ott-11-1801]                   2016   Asian       HB    Osteosarcoma               TaqMan              276     194       71                     11   286     232     49    5    0.21
  Lee et al[@b22-ott-11-1801]                     2017   Asian       HB    Hepatocellular carcinoma   PCR-RFLP            354     290       63                     1    708     594     106   8    0.19
                                                                                                                                                                                                   
  **For WWOX rs12918952 G**\>**A polymorphism**                                                                                                                                                    
                                                                                                                                                                                                   
  Cheng et al[@b21-ott-11-1801]                   2016   Asian       PB    Oral tumor                 TaqMan              761     674       82                     5    1,199   1,088   111   0    0.092
  Huang et al[@b18-ott-11-1801]                   2011   Asian       HB    Lung tumor                 TaqMan              1,056   917       134                    5    1,056   912     138   6    0.753
  Zhang et al[@b20-ott-11-1801]                   2016   Asian       HB    Osteosarcoma               TaqMan              276     251       23                     2    286     257     28    1    0.7996
  Lee et al[@b22-ott-11-1801]                     2017   Asian       HB    Hepatocellular carcinoma   PCR-RFLP            354     310       42                     2    708     637     70    1    0.51
                                                                                                                                                                                                   
  **For WWOX rs383362 G**\>**T polymorphism**                                                                                                                                                      
                                                                                                                                                                                                   
  Cheng et al[@b21-ott-11-1801]                   2016   Asian       PB    Oral tumor                 TaqMan              761     558       199                    4    1,199   887     299   13   0.026
  Huang et al[@b18-ott-11-1801]                   2011   Asian       HB    Lung tumor                 TaqMan              1,559   1,065     441                    53   1,679   1,244   393   42   0.1
  Zhang et al[@b20-ott-11-1801]                   2016   Asian       HB    Osteosarcoma               TaqMan              276     190       77                     9    286     223     57    6    0.3
  Lee et al[@b22-ott-11-1801]                     2017   Asian       HB    Hepatocellular carcinoma   PCR-RFLP            354     282       70                     2    708     529     170   9    0.255

**Abbreviations:** W, wild-type allele; M, mutant-type allele; HB, hospital-based studies; PB, population-based studies; HWE, Hardy--Weinberg equilibrium; PCR-RFLP, polymerase chain reaction--restriction fragment length polymorphism; SOC, source of control.

###### 

Meta-analysis results of the association between WWOX rs3764340 C\>G polymorphism and malignant tumor risk

  Variables            N   Sample size   CG vs CC                GG vs CC   GG/CG vs CC         GG vs CC/GC   G vs C                                                                              
  -------------------- --- ------------- ----------------------- ---------- ------------------- ------------- ----------------------- ------- ------------------- ------- ----------------------- -------
  Total                8   12,783        **1.31 (1.12--1.53)**   0.031      1.36 (0.90--2.04)   0.392         **1.31 (1.11--1.54)**   0.014   1.30 (0.88--1.93)   0.451   **1.28 (1.09--1.50)**   0.009
  Source of control                                                                                                                                                                               
  PB                   3   4,138         **1.33 (1.09--1.61)**   0.312      1.60 (0.89--2.86)   0.831         **1.35 (1.11--1.65)**   0.263   1.53 (0.85--2.74)   0.857   **1.34 (1.11--1.63)**   0.236
  HB                   5   8,645         1.28 (1.00--1.63)       0.011      1.03 (0.48--2.19)   0.165         1.27 (0.99--1.63)       0.005   1.00 (0.49--2.05)   0.204   1.23 (0.97--1.57)       0.004
  Genotyping methods                                                                                                                                                                              
  TaqMan               3   5,760         **1.32 (1.10--1.59)**   0.236      1.58 (0.94--2.66)   0.566         **1.35 (1.10--1.66)**   0.158   1.50 (0.90--2.52)   0.651   **1.34 (1.09--1.63)**   0.133
  PCR--RFLP            4   6,023         **1.46 (1.24--1.72)**   0.691      1.14 (0.53--2.45)   0.239         **1.44 (1.23--1.68)**   0.532   1.09 (0.51--2.32)   0.248   **1.38 (1.09--1.50)**   0.349

**Note:** Bold signifies statistically significant values.

**Abbreviations:** N, number of studies involved; *P*~h~, *P*-value of Q test for heterogeneity; PB, population-based studies; HB, hospital-based studies; PCR-RFLP, polymerase chain reaction--restriction fragment length polymorphism; OR, odds ratio.

###### 

Meta-analysis results of the association between WWOX rs383362 G\>T polymorphism and malignant tumor risk

  Variables            N   Sample size   TG vs GG                TT vs GG   TT+GT vs GG             TT vs GT+GG   T vs G                                                                              
  -------------------- --- ------------- ----------------------- ---------- ----------------------- ------------- ----------------------- ------- ------------------- ------- ----------------------- -------
  Total                4   6,822         1.14 (0.89--1.45)       0.008      1.04 (0.55--1.97)       0.13          1.13 (0.87--1.47)       0.002   1.02 (0.57--1.81)   0.186   1.10 (0.86--1.41)       0.002
  Genotyping methods                                                                                                                                                                                  
  TaqMan               2   3,800         **1.35 (1.16--1.56)**   0.379      **1.51 (1.03--2.22)**   0.758         **1.36 (1.18--1.57)**   0.364   1.40 (0.95--2.05)   0.811   **1.31 (1.16--1.49)**   0.37
  PCR-RFLP             2   3,022         0.92 (0.68--1.25)       0.101      0.46 (0.19--1.15)       0.87          0.90 (0.66--1.23)       0.096   0.47 (0.19--1.16)   0.928   0.89 (0.69--1.17)       0.114

**Note:** Bold signifies statistically significant values.

**Abbreviations:** N, number of studies involved; *P*~h~, *P*-value of Q test for heterogeneity; PCR-RFLP, polymerase chain reaction--restriction fragment length polymorphism; OR, odds ratio.

###### 

Meta-analysis results of the association between WWOX rs12918952 G\>A polymorphism and malignant tumor risk

  Variables            N   Sample size   AG vs GG            AA vs GG   AA+AG vs GG              AA vs AG+GG   A vs G                                                                               
  -------------------- --- ------------- ------------------- ---------- ------------------------ ------------- ------------------- ------- ------------------------ ------- ----------------------- -------
  Total                4   5,696         1.06 (0.90--1.26)   0.523      2.18 (0.62--0.768)       0.216         1.09 (0.92--1.29)   0.38    2.15 (0.62--7.49)        0.223   1.12 (0.92--1.35)       0.254
  Genotyping methods                                                                                                                                                                                
  TaqMan               2   2,674         0.94 (0.75--1.19)   0.668      0.99 (0.34--2.88)        0.509         0.95 (0.75--1.19)   0.789   1.00 (0.34--2.90)        0.504   0.95 (0.77--1.18)       0.921
  PCR-RFLP             2   3,022         1.21 (0.95--1.54)   0.897      **7.46 (1.17--47.48)**   0.446         1.27 (1.00--1.61)   0.98    **7.31 (1.15--46.49)**   0.445   **1.32 (1.05--1.65)**   0.929

**Note:** Bold signifies statistically significant values.

**Abbreviations:** N, number of studies involved; *P*~h~, *P*-value of Q test for heterogeneity; PCR-RFLP, polymerase chain reaction--restriction fragment length polymorphism; OR, odds ratio.

###### 

Results of publication bias test

  Polymorphism      Compared genotype   Begg's test   Egger's test           
  ----------------- ------------------- ------------- -------------- ------- -------
  WWOX rs3764340    CG vs CC            0.87          0.386          0.14    0.893
  GG+CG vs CC       0.87                0.386         0.11           0.917   
  G vs C            0.37                0.711         0.03           0.975   
  WWOX rs12918952   AG vs GG            −0.34         1              −0.1    0.928
  AA+AG vs GG       −0.34               1             0.05           0.965   
  A vs G            −0.34               1             0.18           0.874   
  WWOX rs383362     TG vs GG            0.34          0.734          −0.39   0.736
  TT+GT vs GG       0.34                0.734         −0.44          0.702   
  T vs Gw           0.34                0.734         −0.51          0.659   

[^1]: These authors contributed equally to this work
